Pfizer and BioNTech Announce Success in Vaccine Candidate against SARS-CoV-2
Pfizer and BioNTech SE’s mRNA-based vaccine candidate BNT162b2 is 90% effective in preventing COVID-19 in participants without prior evidence of SARS-COV-2 infection, according to the company’s press release. The results…